What type of study is this?

October 11, 2025

SSRI, SNRI augmentation of clozapine reduces relapse in treatment‐resistant schizophrenia

Key Points

Augmentation of clozapine with either an SSRI or SNRI significantly reduces relapse risks.
This finding is based on cohort data showing that low or standard doses of these antidepressants are effective.
In contrast, augmentation with other antidepressants did not yield similar relapse reduction.
The analysis emphasizes the importance of appropriate medication combinations in managing treatment-resistant schizophrenia.

Abstract

An analysis based on data from two national cohort studies has found that augmentation of clozapine treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonin‐norepinephrine reuptake inhibitor (SNRI) reduces risk of relapse in patients with treatment‐resistant schizophrenia. Augmentation with other antidepressants did not reduce risk of relapse, and the beneficial effects of SSRIs and SNRIs were observed only at low or standard doses of the antidepressants.

Mark Helpful

Bookmark

Relay

Cite This Study

A Fri, study studied this question.

synapsesocial.com/papers/68e9e4c43a308962402362ba https://doi.org/https://doi.org/10.1002/pu.31372

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Mark Helpful

Bookmark

Relay